108Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Russia
Neuroscience Intelligence
Russia neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #31 of 50 · Data maturity A · Research score 33.8 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
11Recruiting trials
19Publications
76Institutions
Executive interpretation
Russia ranks #31 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC123 recruiting
Hoffmann-La Roche111 recruiting
Sumitomo Pharma America, Inc.60 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.50 recruiting
Pfizer51 recruiting
Eli Lilly and Company50 recruiting
Genzyme, a Sanofi Company40 recruiting
GlaxoSmithKline40 recruiting
Boehringer Ingelheim30 recruiting
Ipsen31 recruiting
Disease activity
Parkinsons19trials
Epilepsy18trials
Alzheimers14trials
Depression8trials
Multiple Sclerosis8trials
Other Neurology7trials
Schizophrenia7trials
Stroke7trials
Bipolar Disorder4trials
Neuromuscular4trials
Research institutions
Russian Society of CardiologyOpenAlexlinked institution
Kursk State Medical UniversityOpenAlexlinked institution
Association of Rheumatologists of RussiaOpenAlexlinked institution
Research Institute of InfluenzaOpenAlexlinked institution
Russian University of MedicineOpenAlexlinked institution
North-Western State Medical University named after I.I. MechnikovOpenAlexlinked institution
Ural Institute of CardiologyOpenAlexlinked institution
Institute of Higher Nervous Activity and NeurophysiologyOpenAlexlinked institution
Peoples' Friendship University of RussiaOpenAlexlinked institution
Ministry of Health of the Russian FederationOpenAlexlinked institution
Clinical evidence trail
NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)ACTIVE_NOT_RECRUITING
NCT04879628Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisACTIVE_NOT_RECRUITING
NCT04752774A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.RECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
NCT04544436A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)ACTIVE_NOT_RECRUITING
NCT04281485Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular DystrophyACTIVE_NOT_RECRUITING
NCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseACTIVE_NOT_RECRUITING
NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)ACTIVE_NOT_RECRUITING
NCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentACTIVE_NOT_RECRUITING
NCT06863948Integrative Group Psychotherapy (Terebenin's Method) in Adults With Subclinical and Mild/Moderate Anxiety and DepressionCOMPLETED
Research evidence trail
PUBMEDHippocampal LTP shifts from NMDAR dependence to mGluR/VGCC-supported mechanisms following juvenile status epilepticus in rats.2026-11-17
PUBMEDIntraosseous Lidocaine Trigger Point Injection for Vertebrogenic Pain: From Molecular Principles to Clinical Applications: A Narrative Review.2026-10-08
PUBMEDPhenotypic Profiling of SOD1-G93A Mice: Integrating Sciatic Nerve Histopathology with Systemic Chemokine Dynamics During ALS Progression.2026-09-25
PUBMEDPallidal physiology and predictors of successful deep brain stimulation in jerky dystonia, dystonia with tremor, and their combination.2026-08-01
OPENALEXImmune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives2022-04-25
OPENALEXSafety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia2021-02-01
OPENALEX2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension2018-11-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.